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ABSTRACT
Objective: To assess the prevalence of
microalbuminuria and kidney dysfunction in low-
income countries and in the USA.
Design: Cross-sectional study of screening
programmes in five countries.
Setting: Screening programmes in Nepal, Bolivia, the
USA (National Health and Nutrition Examination Survey
(NHANES) 2005–2008) Bangladesh and Georgia.
Participants: General population in Nepal (n=20 811),
Bolivia (n=3436) and in the USA (n=4299) and high-
risk subjects in Bangladesh (n=1518) and Georgia
(n=1549).
Primary and secondary outcome measures:
Estimated glomerular filtration rate (eGFR)<60ml/min/
1.73 m2 and microalbuminuria (defined as urinary
albumin creatinine ratio values of 30–300 mg/g) were
the main outcome measures. The cardiovascular (CV)
risk was also evaluated on the basis of demographic,
clinical and blood data.
Results: The prevalence of eGFR<60ml/min/1.73 m2
was 19%, 3.2% and 7% in Nepal, Bolivia and the
USA, respectively. In Nepal, 7% of subjects were
microalbuminuric compared to 8.6% in the USA. The
prevalence of participants with predicted 10-year CV
disease (CVD) risk ≥10% was 16.9%, 9.4% and 17%
in Nepal, Bolivia and in the USA, respectively. In
Bangladesh and Georgia, subjects with eGFR<60 ml/
min/1.73 m2 were 8.6% and 4.9%, whereas those
with microalbuminuria were 45.4% and 56.5%,
respectively. Predicted 10-year CVD risk ≥10% was
25.4% and 25% in Bangladesh and Georgia,
respectively.
Conclusions: Renal abnormalities are common
among low-income countries and in the USA.
Prevention programmes, particularly focused on those
with renal abnormalities, should be established
worldwide to prevent CVD and progression to end-
stage renal disease.
ARTICLE SUMMARY
Article focus
▪ Chronic kidney disease, a major risk factor for
cardiovascular morbidity and mortality, is emer-
ging as a worldwide healthcare burden, but data
on its prevalence are very limited, especially in
low-income countries.
▪ The present large, cross-sectional study aimed to
assess prevalence of microalbuminuria in
general population in Nepal, Bolivia and in the
USA, and in high-risk subjects in Bangladesh
and Georgia.
Key messages
▪ We found that about a half of high-risk patients
has some degree of renal impairment, but
reduced kidney function and microalbuminuria/
proteinuria are common also within the general
population, both in low-income countries and in
the USA.
▪ This information will be crucial for implementa-
tion of future screening and intervention pro-
grammes of non-communicable diseases,
especially in the developing countries.
Strengths and limitations of this study
▪ The major strength of the present study is the
large number of subjects included in the screening
programmes that provide crucial information on
the prevalence of kidney disease and cardiovascu-
lar risk in low-income countries and in the USA.
▪ Results from low-income countries cannot be
formally taken to infer the absolute or relative
prevalence of renal abnormalities in these coun-
tries, since subjects were referred to a limited
number of centres. Conversely, data from the
National Health and Nutrition Examination Survey
programme show characteristics of a cohort rep-
resentative of US population.
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INTRODUCTION
Chronic kidney disease (CKD) has emerged as one of
the strongest cardiovascular (CV) risk factors. In the
general population, glomerular ﬁltration rate (GFR)
lower than 60 ml/min/1.73 m2 and albuminuria—one
of the earliest manifestations of CKD—are associated
with an independent risk of CV morbidity and mortal-
ity.1–3 Importantly, albuminuria reduction through ACE
inhibitor or angiotensin receptor blocker therapy is asso-
ciated with a slower renal disease progression and
decreased CV mortality and morbidity.4 5 Thus, since
measurement of renal function and albuminuria is easy
and relatively inexpensive, kidney-targeted detection and
prevention programmes seem to offer a valuable oppor-
tunity to establish early prevention strategies that go
beyond traditional cardioprotective approaches.
Nonetheless, data on the prevalence of renal dysfunc-
tion and microalbuminuria from population screening
programmes in developed countries are scarce. Even
fewer information is available from low-income coun-
tries, where incidence of renal and CV risk factors such
as obesity and diabetes are increasing at an even higher
rate than in developed nations.6
In 2005, the International Society of Nephrology
(ISN) established a Global Outreach Program (formerly
called the Commission on Global Advancement of
Nephrology (COMGAN)) aimed at building global cap-
acity for preventing CKD in developing nations. In 2007,
the ISN funded the establishment of an electronic data-
base (Kidney Disease Data Center (KDDC)) to support
the collection and analysis of data obtained through
ISN-sponsored prevention programmes. In the two
coordinating centres in Nepal and Bolivia, these pro-
grammes have been developed as general population
screenings, providing the unique opportunity to assess
prevalence of renal dysfunction and microalbuminuria/
proteinuria in these areas. In the present study, we ana-
lysed general-population data from these two low-income
country centres and from the National Health and
Nutrition Examination Survey (NHANES), which pro-
vides data from a representative sample of the US civil-
ian non-institutionalised population. Moreover, we
reported data from screening programmes established
in two other centres in Bangladesh and Georgia that
focused on high-risk populations, such as subjects with
hypertension, diabetes mellitus (DM), prior kidney
disease or CV (heart/stroke) disease.
METHODS
Details of screening programs
Given variability in local resources, the programmes
were implemented differently in each location. Details
of the single screening programmes, including numbers
of screening centres within each country are listed in
table 1. Programmes established in Nepal and Bolivia
included general populations. The programme estab-
lished in Nepal included subjects ≥18 years old and was
conducted in the community in Dharan, a city in
eastern Nepal as follows. Dharan has 19 wards and the
screening started from ward 1 and progressed sequen-
tially to ward 2, ward 3 and so on.
All subjects older than 18 years were considered eligible
for the evaluation in Bolivia. The screening programme
was conducted in the community in the city of La Paz and
El Alto located in Murillo province of the same depart-
ment. The screening camp was organised in the Unit
Nephrology Service at Hospital Juan XXIII. On the day of
screening people were asked to come to the centre.
On the day of the screening, the subjects were
enrolled after being informed on the objective of the
survey, the procedures, the information that could be
drawn for the survey and the potential beneﬁts of such
screening.
Entry criteria for Bangladesh and Georgia included
known hypertension, DM, prior kidney or CV (heart/
stroke) disease. Information from the NHANES screen-
ing programme of the US population is reported in
table 1. Further details are available at http://www.cdc.
gov/nchs/nhanes.htm.
Data from low-income countries were collected pro-
spectively by the staff of the screening programmes,
using the same cut-off points for clinical and laboratory
parameters and the same web-based database and the
same cut-off criteria at all participating sites. Data quality
was monitored by the bioengineer team of the Clinical
Research Center for Rare Diseases, ‘Aldo e Cele Dacco’’,
Bergamo, Italy.
Baseline data obtained from each participant included
age, gender, marital and employment status, education
level, smoking status, alcohol use, DM status and per-
sonal history of hypertension and kidney disease. Height
and weight were measured and used to calculate body
mass index (BMI). Systolic (SBP) and diastolic blood
pressures (DBP) were measured by trained personnel
using manual sphygmomanometers after participants
rested quietly for at least 5 min.
Blood and urine specimens were provided by partici-
pants according to local protocols determined by the
availability of resources (table 1). Urinary protein/
albumin excretion was assessed, respectively, by dipstick
and urinary albumin creatinine ratio (ACR) in Nepal and
Georgia, by dipstick alone in Bolivia and by ACR alone in
the USA. The screening programme in Bangladesh evalu-
ated albumin excretion by Albustick. Results of urinalysis
were interpreted by trained and experienced personnel
working in appropriate conditions. Follow-up of abnor-
malities identiﬁed during screening varied, depending
on local resources (table 1). Screening was carried out
under research protocols approved in advance by the
relevant institutional review boards.
Definitions of microalbuminuria, hypertension, diabetes,
obesity and decreased estimated GFR
Microalbuminuria was deﬁned as urinary ACR values of
30–300 mg/g. Subjects with ACR lower than 30 mg/g
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Table 1 Details of participating screening programmes by country
Nepal Bolivia USA-NHANES
Setting Community-based, using a
combination of permanent
centres (health clinics, community
centres, etc) and temporary
screening centres (schools,
clubs, houses of worship and
private homes)
General population of the city
of La Paz and El Alto attending
to the screening centre at the
Hospital Juan XXIII
The survey examines a
nationally representative sample
of about 5000 persons (aged
1 year and older) each year.
Health interviews are conducted
in respondents’ homes. Health
measurements are performed in
specially designed and
equipped mobile centres, which
travel to locations throughout
the country
Number of
centres
Eight permanent centres with
variable numbers of temporary
centres
One permanent centre A nation-wide screening
programme, designed to obtain
a statistically representative
sample of the US population
and many relevant demographic
subgroups
Timing Year-round Year-round Year-round
Inclusion
criteria
Age ≥18 years Age >18 years Age >18 years
Exclusion
criteria
Pregnancy and any acute illness Pregnancy and any acute
illness
Pregnancy and any acute
illness
Measurements Interview including demographic,
socioeconomic, dietary and
health-related questions. Fasting
serum creatinine, glucose, total
cholesterol and triglycerides,
dipstick urinalysis with proteinuria
confirmed by ACR
Interview including
demographic, socioeconomic,
dietary and health-related
questions. Fasting serum
creatinine, glucose, dipstick
urinalysis with proteinuria
The NHANES interview
includes demographic,
socioeconomic, dietary and
health-related questions.
The examination component
consists of medical, dental and
physiological measurements, as
well as laboratory tests
administered by highly trained
medical personnel. Specific in
kidney-related laboratory
measurements included fasting
serum creatinine, glucose, total
cholesterol and triglycerides and
urinary ACR
Clinic staff Trained community volunteers,
medical students, nurses,
physicians, laboratory technicians
Physicians, nurses, laboratory
technicians, medical students
Physician, medical and health
technicians, as well as dietary
and health interviewers
Advertising/
promotion
Community health education:
publicity (videos, leaflets,
pamphlets, banners, radio/
television programmes news
paper articles) targeted
education/distribution of written
materials to people at risk,
students and physicians
Community health education:
through leaflets, videos,
television, news paper articles,
organisation of World Kidney
Day
In each location, local health
and government officials are
notified of the upcoming survey.
Households in the study area
receive a letter from the NCHS
Director to introduce the survey.
Local media may feature stories
about the survey
Follow-up visits People found to have CKD,
diabetes or hypertensions were
seen monthly for 1–3 month then
every 3–6 month
People found to have
hypertension, diabetes, CKD
were advised for treatment and
life style modification and
asked to come back at
3–6 month intervals
No follow-up arranged.
However, participants will
receive Report of Findings in
the mail 12-16 weeks after the
exam
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were deﬁned as normoalbuminuric, those with more
than 300 mg/g as macroalbuminuric. Positive Albustick
identiﬁed patients with microalbuminuria. Results of dip-
stick urinalysis were considered to indicate macroalbumi-
nuria if they showed protein of 1+ or more. Hypertension
was classiﬁed according to the Seventh Report of the
Joint National Committee on Prevention, Detection,
Evaluation and Treatment of High Blood Pressure
scheme.7 Participants were classiﬁed as having DM if they
reported a history of or were currently treated for DM.
Serum creatinine was used to estimate GFR using the
Modiﬁcation of Diet in Renal Disease (MDRD) Study
equation in all participants.8 Because the MDRD Study
equation is less accurate at higher levels of true GFR, par-
ticipants were classiﬁed regarding the presence or
absence of estimated GFR (eGFR)<60 ml/min/1.73 m2
(termed ‘decreased eGFR’). Participants’ BMI was classi-
ﬁed according to the current WHO9 scheme as
follows: <18.49 (underweight), 18.5–24.9 (reference
range), 25–29.9 (preobese) and ≥30 kg/m2 (obese).
The likelihood of a serious CV outcome (death, myo-
cardial infarction, stroke, heart failure or coronary revas-
cularisation) during the next 10 years was estimated by
using WHO charts for each studied country (available at
http://www.ish-world.com/Documents/colour_charts_24_
Aug_07.pdf).
Table 1 Continued
Bangladesh Georgia
Setting A multistaged prospective study done in all eligible
subjects of the village Mollargaon in Sylhet
The Project emphasises two phases. The phase I
comprises of screening of target population to
determine patients with chronic renal injury,
diabetes, hypertension, cardiovascular disease.
Phase II: People eligible for the comprehensive
management programme were screened. All
patients have been admitted to the leading hospitals
of main cities of all regions of Georgia
Number of
centres
One temporary centre Seven permanent centres
Timing 8 months
Inclusion criteria Age >18 years. High-risk subjects identified among
those with hypertension, diabetes, prior CKD or
prior heart attack or stroke at first stage screening/
interview
All patients who have been admitted to the leading
hospitals of main cities of all regions of Georgia
during last 10 years with the following reasons:
▸ Chronic pyelonephritis
▸ Chronic glomerulonephritis
▸ Nephrolithiasis/urolithiasis
▸ Kidney cystic disease
▸ Multicystic dysplastic kidney
▸ Congenital malformations with renal function
impairment
▸ Hypertension
▸ Heart attack/stroke
▸ Chronic renal failure
▸ Diabetes mellitus
▸ Tubulo-interstitial nephritis
Exclusion
criteria
Pregnancy and any acute illness Patients without confirmed medical diagnoses
(based on medical documentation) excluded
Measurements Interview including demographic, socioeconomic,
dietary and health-related questions; serum
creatinine, fasting glucose, dipstick albuminuria
Patient interview includes demographic,
socioeconomic, dietary and health-related questions;
physical examination and fasting serum creatinine,
fasting glucose, total cholesterol, dipstick urinalysis
for proteinuria and urinary ACR (repeated if positive)
Clinic staff Doctors, nurses, health workers, medical students,
laboratory technicians
Physicians, nurses and students trained to take part
in data collection of the project
Advertising/
promotion
Local community leaders and health workers were
first contacted, the study was explained and
showed them the medical information pamphlet
The appropriate education material for patients as
well as for medical staff elaborated for further spread
and acknowledgement
Follow-up visits No follow-up arranged Patients are followed up twice in the first month of
the treatment period, particularly to monitor potential
ACE inhibitor complications. Follow-up assessment
made every 6 months
ACR, albumin creatinine ratio; CKD, chronic kidney disease NHANES, National Health and Nutrition Examination Survey.
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Statistical analyses
Descriptive statistics were tabulated by country using
count and percentage with CI or median and IQR, as
appropriate. Missing values were not analysed and case-
wise deletion did not occur; therefore, the total number
of participants varied by variable. Outcomes of interest
included hypertension, proteinuria, eGFR<60 ml/min/
1.73 m2, DM, BMI and CV risk. According to the WHO
charts, the 10-year risk of a fatal or non-fatal CV event
considered the following parameters: age (years),
gender, smoking habit, SBP (mm Hg) and presence/
absence of DM. A SAS V.9.1 code was constructed to
generate the 10-year CV risk class for each participant.
Results were stratiﬁed by gender, age, prior DM status
and prior CV disease (CVD) status. Differences in listed
variables between genders were analysed using
Cochran-Mantel-Haenszel test—analysis of variance type
or χ2 test, as appropriate.
Age-adjusted eGFR<60ml/min/1.73 m2 and ACR>30
prevalence estimates were adjusted by the direct method
to the year 2000 US Census population using the age
groups 18–24, 25–34, 35–44, 45–54 and 55 years and
older. The 95% CIs were calculated using Taylor series
linearisation.
Statistical analyses were performed using Stata soft-
ware, V.12.0 (StataCorp, www.stata.com) for low-income
countries and SAS-callable SUDAAN statistical software
V.10.0 (Research Triangle Institute, Research Triangle
Park, North Carolina, USA) to account for the complex
survey sample design for the USA.
RESULTS
Participant characteristics
Table 2 shows demographic and clinical characteristics
of the 31 613 participants.
General populations
Median age of participants and gender distribution were
similar between the two general population screening
cohorts in Nepal and Bolivia and in the USA. Levels of
education were variable across nations, with people from
Bolivia and the USA showing the highest fraction of sub-
jects with more than 10 years of education. Prevalence
of smoking habit was lower than 15% in both low-
income countries, whereas it approximated 25% in US
subjects. Levels of activity, vegetable intake and alcohol
consumption were variable. Bolivian subjects had the
highest prevalence of positive familiar history for CKD,
hypertension, CVD and diabetes. At physical examin-
ation, US participants showed highest levels of BMI,
whereas median blood pressure levels were within the
normal range for all countries.
High-risk populations
High-risk subjects included in Bangladesh and Georgia
programmes were older than in general population
screenings and more frequently female. Level of
education was relatively low in both countries, with
people from Bangladesh showing the lower fraction of
subjects with more than 10 years of education.
Prevalence of smoking habit was almost 30% in
Bangladesh and 10% in Georgia. Level of activity was
high, with more than 70% of subjects in Bangladesh and
50% in Georgia doing more than 1 h/day of physical
activity. Vegetable intake and alcohol consumption were
variable. Georgian subjects had the highest prevalence
of family history of CKD, hypertension, CVD and dia-
betes. By physical examination, they also showed the
highest levels of BMI, whereas those from Bangladesh
had the highest levels of blood pressure.
Prevalence of hypertension, eGFR<60 ml/min/1.73 m2
and albuminuria
General populations
Within general population screening programmes,
Nepalese participants had the highest prevalence of
hypertension (assessed at the clinical visit). In each
general population programme, the prevalence of
hypertension was higher in participants who were male,
older than 60 years, or had a history of DM or CVD
(table 3).
The prevalence of eGFR<60 ml/min/1.73 m2 was
highly variable, ranging from 3.2% in Bolivia to 19% in
Nepal. The fraction of US participants with
eGFR<60 ml/min/1.73 m2 was 7%. In these nations, the
prevalence of eGFR<60 ml/min/1.73 m2 was higher in
male subjects and in participants older than 60 years
and in those with prior DM or CVD.
The prevalence of microalbuminuria was similar
between Nepal and the USA. Only a minority of patients
(13.3%) with microalbuminuria in Nepal was positive
for proteinuria (≥1+) at urinary dipstick. To take into
account for the difference in the age distributions of the
programmes examined, we performed age-adjusted
prevalence estimates of eGFR<60 ml/min/1.83 m2 and
ACR>30. As shown in table 4, age-adjusted analyses con-
ﬁrmed crude data of the prevalence of renal dysfunction
in these countries.
Roughly the same prevalence of proteinuria (≥1+) was
found in Nepal and Bolivia. In analogy with hyperten-
sion, the higher prevalence of microalbuminuria and
proteinuria was found within subjects who were male,
older than 60 years, or who had a history of DM
or CVD.
The proportion of participants who had both
eGFR<60 ml/min/1.73 m2 and microalbuminuria or
macroalbuminuria was 2.1% and 1.4% in Nepal and
Bolivia, respectively. The proportion of participants with
both heavy proteinuria (≥3+) and eGFR<60 ml/min/
1.73 m2 was markedly lower (Nepal 0.1%, Bolivia 0.5%).
High-risk populations
Subjects included in the high-risk population screenings
had a high prevalence of hypertension, with almost one-
fourth of those in Georgia with stage 2 hypertension.
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Table 2 Demographics and clinical characteristics of participants in screening programmes
Community screenings High-risk population screenings
Nepal Bolivia USA Bangladesh Georgia
Participants (n) 20811 3436 4299 1518 1549
Age (year) 39 (27 to 51) 40 (31 to 51) 45 (32 to 58) 48 (38 to 60) 52 (18 to 85)
Women 61.4 (60.8 to 62.1) 63.8 (62.2 to65.4) 50.6 (49.0 to 52.1) 56.6 (54.1 to 59.1) 74.6 (72.4 to 76.8)
Married 82.7 (82.2 to 83.2) 68.4 (66.8 to 69.9) 56.6 (54.0 to 59.2) 91.0 (89.4 to 92.4) 89.7 (88.0 to 91.2)
Education (years)
>10 35.5 (34.8 to 36.3) 56.1 (54.4 to 57.8) 55.6* (51.8 to 59.3) 4.2 (3.3 to 5.4) 38.1 (35.6 to 40.7)
6–10 21.9 (21.3 to 22.5) 19.6 (18.3 to 21.0) 38.1† (34.8 to 41.4) 13.7 (12.0 to 15.5) 57.0 (54.4 to 59.5)
1–5 14.3 (13.8 to 14.9) 21.0 (19.6 to 22.4) 6.3‡ (5.4 to 7.4) 32.3 (29.9 to 34.7) 3.3 (2.4 to 4.4)
None 28.2 (27.5 to 28.9) 3.4 (2.8 to 4.0) 49.8 (47.2 to 52.4) 1.6 (1.0 to 2.4)
Work
Physical labour 10.4 (10.0 to 10.8) 5.1 (4.4 to 5.9) 29.0 (26.7 to 31.4) 9.7 (8.2 to 11.3)
Office work 17.4 (16.9 to 17.9) 21.7 (20.3 to 23.1) 3.1 (2.3 to 4.1) 22.0 (19.9 to 24.3)
House work 52.9 (52.2 to 53.6) 28.2 (26.7 to 29.7) 48.9 (46.3 to 51.4) 31.2 (28.8 to 33.7)
Unemployed 14.2 (13.8 to 14.7) 45.1 (43.4 to 46.7) 19.0 (17.1 to 21.1) 37.1 (34.6 to 39.7)
Fruit/vegetable intake
1×/day 30.9 (30.3 to 31.5) 8.5 (7.6 to 9.5) 5.6 (4.5 to 6.8) 45.9 (43.3 to 48.5)
3–5×/day 58.0 (57.4 to 58.7) 61.7 (60.1 to 63.4) 60.8 (58.3 to 63.3) 41.8 (39.3 to 44.4)
1×/week 10.2 (9.8 to 10.7) 28.9 (27.3 to 30.4) 32.3 (29.9 to 34.7) 7.6 (6.3 to 9.1)
None 0.8 (0.7 to 9.5) 0.9 (0.6 to 1.2) 1.3 (0.8 to 2.1) 4.7 (3.7 to 5.9)
Smoking
Current 13.2 (12.8 to 13.7) 11.7 (10.7 to 12.9) 23.6 (21.1 to 26.2) 29.2 (26.9 to 31.6) 10.3 (8.8 to 12.0)
Former 9.4 (9.0 to 9.8) 7.4 (6.5 to 8.3) 24.9 (23.0 to 27.0) 2.9 (2.1 to 3.9) 4.4 (3.4 to 5.6)
No 77.3 (76.8 to 77.9) 80.9 (79.5 to 82.2) 51.5 (48.6 to 54.3) 67.9 (65.5 to 70.2) 85.3 (83.4 to 87.1)
Alcohol
1×/day 7.4 (7.1 to 7.8) 0.4 (0.2 to 0.6) 5.7 (4.6 to 7.1) 1.6 (1.0 to 2.4)
1×/week 6.5 (6.2 to 6.9) 5.0 (4.3 to 5.8) 31.6 (29.2 to 34.1) 10.6 (9.0 to 12.2)
1×/month 11.8 (11.3 to 12.2) 36.4 (34.8 to 38.0) 43.3 (41.0 to 45.7) 0.3 – 19.1 (17.1 to 21.2)
None 74.3 (73.7 to 74.9) 58.2 (56.5 to 59.8) 19.4 (17.3 to 21.6) 99.7 (99.2 to 99.9) 68.7 (66.2 to 71.1)
Physical activity (min/day)
>60 33.3 (32.7 to 34.0) 23.0 (21.6 to 24.5) 73.6 (71.3 to 75.8) 55.3 (52.7 to 58.0)
30–60 23.2 (22.6 to 23.8) 43.7 (42.0 to 45.4) 5.7 (4.6 to 7.0) 19.1 (17.01 to 21.2)
<30 21.0 (20.5 to 21.6) 27.0 (25.5 to 28.5) 2.5 (1.8 to 3.4) 14.2 (12.4 to 16.2)
None 22.4 (21.9 to 23.0) 6.3 (5.5 to 7.1) 18.2 (16.3 to 20.3) 11.4 (9.7 to 13.1)
Family history
CKD 2.3 (2.1 to 2.6) 12.3 (11.2 to 13.4) 0.8 (0.4 to 1.4) 26.4 (24.1 to 28.7)
HTN 22.0 (21.4 to 22.6) 29.1 (27.6 to 30.6) 18.5 (16.6 to 20.5) 61.5 (58.9 to 64.0)
DM 11.9 (11.4 to 12.3) 17.6 (16.3 to 18.9) 6.3 (5.1 to 7.6) 29.8 (27.4 to 32.2)
MI/CVD 3.4 (3.2 to 3.6) 12.3 (11.2 to 13.4) 0.7 – 25.2 (23.0 to 27.6)
Continued
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The prevalence of hypertension was higher in male par-
ticipants and in those older than 60 years, or with a
history of DM or CVD (table 3).
In Bangladesh, 45.4% of screened subjects had posi-
tive albumin dipstick. More than 50% of screened sub-
jects in Georgia had microalbuminuria and 14% had
proteinuria (≥1+). Male gender, older age and a history
of DM or CVD were associated with higher levels of pro-
teinuria in both nations. The proportion of participants
who had both eGFR<60 ml/min/1.73 m2 and microalbu-
minuria or macroalbuminuria was 4.8% in Bangladesh
and 2.9% in Georgia. The proportion of participants
with both heavy proteinuria (≥3+) and eGFR<60 ml/
min/1.73 m2 was markedly lower in Georgia (0.5%)
where both these measurements were performed.
Prevalence of DM, obesity/underweight and distribution
of CV risk
General populations
Subjects with DM (assessed at the clinical visit) were
5.9% in Nepal, 2.6% in Bolivia and 7.9% in the USA. In
all the countries, prevalence of DM progressively
increased with BMI. No signiﬁcant difference was found
in the prevalence of DM between female and male sub-
jects in Bolivia and in the USA. Conversely, DM was sig-
niﬁcantly more frequent among males in Nepal
programme. Except for Bolivia, where all people with
hyperglycaemia had a previous diagnosis of DM, 3.5%
and 2.9% of subjects found hyperglycaemic during
Nepal and US screening programmes did not have a
previous diagnosis of DM. The prevalence of under-
weight was highest among Nepalese subjects, whereas
that of obese subjects was highest in Bolivia (table 5).
The prevalence of participants with predicted 10-year
CV risk ≥10% was 16.9%, 9.4% and 17.0% in Nepal,
Bolivia, and the USA, respectively (table 6).
High-risk populations
Subjects with DM were frequent both in Bangladesh
(9.6%) and in Georgia (15.2%), with 8.5% and 4.4% of
subjects with fasting hyperglycaemia having no previous
diagnosis of DM, respectively. Prevalence of DM was
similar between female and male subjects in both
Bangladesh and Georgia. A complementary pattern of
nutritional status was found in the two nations. Almost
one-ﬁfth of subjects in Bangladesh were undernour-
ished, with only 1.4% of obese people in the nation.
Conversely, undernourishment was seen in only 2.6%
of Georgian people and 37.4% of cases were obese
(table 5). The prevalence of participants with predicted
10-year CV risk≥10% was 25.4% in Bangladesh and
25.0% in Georgia (table 6).
DISCUSSION
The present large screening programmes of general
populations showed a high prevalence of eGFR<60 ml/
min/1.73 m2 and microalbuminuria in Nepal and
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Table 3 Prevalence of hypertension, urinary abnormalities and kidney dysfunction in participants by country
Number of
participants
HTN Proteinuria ACR eGFR (ml/min/1.73 m2)
Pre-HTN Stage 1 Stage 2 1+ 2+ 3+ 30–300 >300 30–59.9 15–29.9 <15
Nepal
All 20811 8121 (39.0) 4665 (22.4) 2229 (10.7) 503 (2.4) 162 (0.8) 58 (0.3) 604 (7.0) 6 (0.1) 3859 (18.6) 56 (0.3) 16 (0.1)
(38.4 to 39.7) (21.9 to 23.0) (10.3 to 11.1) (2.2 to 2.6) (0.7 to 0.9) (0.2 to 0.4) (6.4 to 7.5) – (18.1 to 19.2) (0.2 to 0.4) (0.0 to 0.1)
Gender
Women 12792 4895 (38.3) 2529 (19.8) 1171 (9.2) 297 (2.3) 87 (0.7) 36 (0.3) 340 (6.3) 3 (0.1) 2677 (21) 28 (0.2) 9 (0.1)
(37.4 to 39.1) (19.1 to 20.5) (8.7 to 9.7) (2.1 to 2.6) (0.5 to 0.8) (0.2 to 0.4) (5.7 to 7.0) – (20.3 to 21.7) (0.1 to 0.3) –
Men 8019 3226 (40.2) 2136 (26.6) 1058 (13.2) 206 (2.6) 75 (0.9) 22 (0.3) 264 (8) 3 (0.1) 1182 (14.8) 28 (0.4) 7 (0.1)
(39.2 to 41.3) (25.7 to 27.6) (12.5 to 14.0) (2.2 to 3.0) (0.7 to 1.2) (0.2 to 0.4) (7.1 to 8.9) – (14.0 to 15.6) (0.2 to 0.5) –
Age (years)
18–40 11283 4922 (43.6) 1617 (14.3) 473 (4.2) 199 (1.8) 47 (0.4) 21 (0.2) 207 (4.4) 2 (0.0) 997 (8.9) 12 (0.1) 4 (0.0)
(42.7 to 44.6) (13.7 to 15.0) (38.3 to 45.8) (1.5 to 2.0) (0.3 to 0.6) (0.1 to 0.3) (3.8 to 5.0) – (8.4 to 9.4) (0.0 to 0.2) –
41–60 6973 2500 (35.9) 2137 (30.6) 1089 (15.6) 180 (2.6) 65 (0.9) 16 (0.2) 267 (9.3) 2 (0.1) 1681 (24.2) 24 (0.3) 7 (0.1)
(34.7 to 37.0) (29.6 to 31.7) (14.8 to 16.5) (2.2 to 3.0) (0.7 to 1.2) (0.1 to 0.4) (8.2 to 10.4) – (23.2 to 25.2) (0.2 to 0.5) –
>60 2555 699 (27.4) 911 (35.7) 667 (26.1) 124 (4.9) 50 (2.0) 21 (0.8) 130 (12.3) 2 (0.2) 1181 (46.3) 20 (0.8) 5 (0.2)
(25.6 to 29.1) (33.8 to 37.5) (24.4 to 27.9) (4.1 to 5.8) (1.5 to 2.6) (0.5 to 1.3) (10.4 to 14.5) – (44.4 to 48.3) (0.5 to 1.2) –
Prior DM 1330 441 (33.2) 455 (34.2) 268 (20.2) 66 (5.0) 41 (3.1) 17 (1.3) 154 (25.8) 3 (0.5) 393 (29.7) 17 (1.3) 3 (0.2)
(30.6 to 35.8) (31.7 to 36.8) (18.0 to 22.4) (3.9 to 6.3) (2.2 to 4.2) (0.7 to 2.0) (22.3 to 29.5) – (27.2 to 32.2) (0.7 to 2.0) –
No prior DM 16623 6531 (39.3) 3644 (21.9) 1647 (9.9) 385 (2.3) 110 (0.7) 39 (0.2) 424 (5.3) 3 (0.04) 2868 (17.3) 34 (0.2) 12 (0.1)
(38.6 to 40.0) (21.3 to 22.6) (9.5 to 10.4) (2.1 to 2.6) (0.5 to 0.8) (0.2 to 0.3) (4.8 to 5.8) – (16.8 to 18.0) (0.1 to 0.3) (0.0 to 0.1)
Prior CVD 304 105 (34.5) 78 (25.7) 64 (21.1) 20 (6.6) 4 (1.3) 4 (1.3) 20 (14.9) 1 (0.7) 99 (32.7) 3 (1.0) 0 (0.0)
(29.2 to 40.2) (20.8 to 31.0) (16.6 to 26.1) (4.1 to 10.0) – – (9.4 to 22.1) – (27.4 to 38.3) – –
No prior CVD 17737 6920 (39.0) 4020 (22.7) 1856 (10.5) 421 (2.4) 141 (0.8) 52 (0.3) 561 (6.6) 5 (0.1) 3159 (17.9) 46 (0.3) 15 (0.1)
(38.3 to 39.7) (22.1 to 23.3) (10.0 to 10.9) (2.2 to 2.6) (0.7 to 0.9) (0.2 to 0.4) (6.1 to 7.1) – (17.3 to 18.5) (0.2 to 0.3) (0.0 to 0.1)
Bolivia
All 3436 896 (26.1) 312 (9.1) 104 (3.0) 60 (1.8) 65 (1.9) 27 (0.8) 45 (2.4) 7 (0.4) 8 (0.4)
(24.6 to 27.6) (8.1 to 10.1) (2.5 to 3.7) (1.4 to 2.3) (1.5 to 2.4) (0.5 to 1.2) (1.8 to 3.2) – –
Gender
Women 2192 485 (22.1) 155 (7.1) 67 (3.1) 34 (1.6) 37 (1.7) 14 (0.7) 23 (1.9) 4 (0.3) 5 (0.4)
(20.4 to 23.9) (6 to 8.2) (2.4 to 3.9) (1.1 to 2.2) (1.2 to 2.3) (0.4 to 1.1) (1.2 to 2.8) – –
Men 1244 411 (33.1) 157 (12.6) 37 (3) 26 (2.1) 28 (2.3) 13 (1.1) 22 (3.5) 3 (0.5) 3 (0.5)
(30.5 to 35.8) (10.8 to 14.6) (2.1 to 4.1) (1.4 to 3.1) (1.5 to 3.3) (0.6 to 1.8) (2.2 to 5.2) – –
Age (years)
18–40 1732 333 (19.2) 62 (3.6) 10 (0.6) 29 (1.7) 16 (0.9) 8 (0.5) 6 (0.7) 1 (0.1) 0
(17.4 to 21.2) (2.8 to 4.6) – (1.1 to 2.4) (0.5 to 1.5) – – –
41–60 1386 436 (31.5) 173 (12.5) 64 (4.6) 20 (1.5) 32 (2.3) 17 (1.2) 14 (1.9) 4 (0.5) 5 (0.7)
(29.0 to 34) (10.8 to 14.3) (3.6 to 5.9) (0.9 to 2.2) (1.6 to 3.3) (0.7 to 2.0) (1.0 to 3.1) – –
>60 318 127 (39.9) 77 (24.2) 30 (9.4) 11 (3.5) 17 (5.4) 2 (0.6) 25 (12.5) 2 (1.0) 3 (1.5)
(34.5 to 45.6) (19.6 to 29.3) (6.5 to 13.2) (1.8 to 6.2) (3.2 to 8.6) – (8.3 to 17.9) – –
Prior DM 87 20 (23.0) 27 (31.0) 8 (9.2) 3 (3.5) 11 (12.9) 8 (9.4) 4 (8.0) 3 (6.0) 1 (2.0)
(14.6 to 33.2) (21.5 to 41.9) – – (6.6 to 22.0) – – – –
No prior DM 2393 619 (25.9) 198 (8.3) 68 (2.8) 49 (2.1) 38 (1.6) 16 (0.7) 30 (2.6) 1 (0.1) 5 (0.4)
(24.1 to 27.7) (7.2 to 9.5) (2.2 to 3.6) (1.5 to 2.7) (1.1 to 2.2) (0.4 to 1.1) (1.7 to 3.6) – –
Prior CVD 71 21 (30.0) 15 (21.4) 5 (7.1) 5 (7.4) 5 (7.4) 2 (2.9) 1 (2.4) 0 0
(19.6 to 42.1) (12.5 to 32.9) – – – – –
Continued
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Table 3 Continued
Number of
participants
HTN Proteinuria ACR eGFR (ml/min/1.73 m2)
Pre-HTN Stage 1 Stage 2 1+ 2+ 3+ 30–300 >300 30–59.9 15–29.9 <15
No prior CVD 2718 696 (25.6) 236 (8.7) 74 (2.7) 48 (1.8) 46 (1.7) 20 (0.7) 36 (2.5) 3 (0.2) 6 (0.4)
(24 to 27.3) (7.7 to 9.8) (2.1 to 3.4) (1.3 to 2.4) (1.3 to 2.3) (0.5 to 1.1) (1.8 to 3.5) – –
US
All 4299 1508 (25.5) 280 (5.8) 74 (1.3) 499 (8.6) 109 (1.8) 337 (6.4) 30 (0.5) –
(23.4 to 27.6) (5.0 to 6.7) (1.0 to 1.6) (7.5 to 9.8) (1.5 to 2.3) (5.3 to 7.8) (0.4 to 0.6)
Gender
Women 2091 396 (19.5) 112 (4.8) 28 (0.9) 256 (9.7) 58 (2.0) 184 (7.9) 17 (0.6) –
(17.2 to 22.1) (3.9 to 5.9) (0.6 to 1.3) (8.1 to 11.5) (1.4 to 2.8) (6.3 to 9.8) (0.4 to 0.9)
Men 2208 662 (31.5) 168 (6.8) 46 (1.7) 243 (7.5) 51 (1.7) 153 (4.9) 13 (0.3) –
(28.9 to 34.3) (5.6 to 8.3) (1.2 to 2.3) (6.5 to 8.8) (1.2 to 2.5) (3.8 to 6.4) (0.2 to 0.6)
Age (year)
18–40 1652 440 (25.1) 56 (3.3) – 103 (6.3) – – 0 0
(22.3 to 28.1) (2.3 to 4.5) (5.0 to 8.0)
41–60 1337 377 (30.1) 107 (7.2) – 126 (6.4) 33 (2.0) 44 (4.0) – –
(26.3 to 34.2) (5.8 to 8.9) (4.9 to 8.3) (1.3 to 3.0) (2.7 to 6.0)
>60 1310 241 (17.6) 117 (8.2) 47 (3.1) 270 (17.1) 63 (4.1) 291 (23.0) 24 (1.8) –
(15.7 to 19.8) (6.6 to 10.3) (2.3 to 4.2) (14.6 to 19.8) (2.8 to 5.7) (20.3 to 25.9) (1.3 to 2.5)
Prior DM 516 62 (12.9) 38 (6.4) – 148 (25.5) 56 (9.6) 84 (14.1) 17 (2.9) –
(10.3 to 16.2) (4.5 to 9.0) (19.9 to 32.1) (6.7 to 13.6) (10.6 to 18.6) (2.0 to 4.2)
No prior DM 3779 995 (26.6) 242 (5.7) 66 (1.3) 350 (7.1) 53 (1.1) 253 (5.7) 13 (0.3) –
(24.5 to 28.9) (4.9 to 6.7) (1.0 to 1.7) (6.1 to 8.2) (0.9 to 1.5) (4.7 to 7.0) (0.2 to 0.4)
Prior CVD* 467 49 (11.0) 26 (4.9) – 120 (21.7) 40 (8.2) 116 (22.2) 18 (3.4) –
(7.3 to 16.1) (3.4 to 7.0) (16.9 to 27.4) (5.1 to 13.1) (17.7 to 27.5) (2.5 to 4.7)
No prior CVD* 3493 921 (27.0) 248 (6.1) 65 (1.3) 344 (7.2) 68 (1.3) 217 (5.1) – –
(24.8 to 29.3) (5.2 to 7.0) (1.0 to 1.6) (6.3 to 8.4) (1.0 to 1.5) (4.1 to 6.4)
Bangladesh
All 1518 533 (35.5) 621 (41.4) 210 (14) 690 (45.4)† 108 (7.1) 21 (1.4) 2 (0.1)
(33.1 to 38.0) (38.9 to 43.9) (12.3 to 15.8) (42.9 to 48.0) (5.9 to 8.6) (0.9 to 2.1) –
Gender
Women 859 289 (34.1) 380 (44.8) 112 (13.2) 364 (42.4) 63 (7.4) 15 (1.7) 1 (0.1)
(30.9 to 37.4) (41.4 to 48.2) (11.0 to 15.7) (39.0 to 45.8) (5.7 to 9.3) (1.0 to 2.9) –
Men 659 244 (37.4) 241 (36.9) 98 (15) 326 (49.5) 45 (6.9) 6 (0.9) 1 (0.1)
(33.6 to 41.2) (33.2 to 40.7) (12.4 to 18.0) 45.6 to 53.4) (5.0 to 9.1) – –
Age (years)
18–40 575 244 (42.7) 203 (35.5) 64 (11.2) 369 (64.2) 40 (7) 4 (0.7) 2 (0.3)
(38.6 to 46.8) (31.6 to 39.6) (8.7 to 14.1) (60.1 to 68.1) (5.0 to 9.4) – –
41–60 690 198 (29.1) 327 (48.1) 105 (15.4) 202 (29.3) 45 (6.5) 10 (1.4) 0
(25.7 to 32.7) (44.3 to 51.9) (12.8 to 18.4) (25.9 to 32.8) (4.8 to 8.7) –
>60 253 91 (36.6) 91 (36.6) 41 (16.5) 119 (47.0) 23 (9.2) 7 (2.8) 0
(30.6 to 42.9) (30.6 to 42.9) (12.1 to 21.7) (40.8 to 53.4) (5.9 to 13.4) –
Prior DM 111 53 (48.2) 36 (32.7) 14 (12.7) 32 (28.8) 11 (9.9) 8 (7.2) 0
(38.6 to 57.9) (24.1 to 42.3) (7.1 to 20.4) (20.6 to 38.2) (5.1 to 17.0) –
No prior DM 1404 478 (34.4) 584 (42.1) 196 (14.1) 656 (46.7) 97 (6.9) 13 (0.9) 2 (0.1)
(31.9 to 37.0) (39.5 to 44.7) (12.3 to 16.1) (44.1 to 49.4) (5.7 to 8.4) (0.5 to 1.6) –
Continued
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Table 3 Continued
Number of
participants
HTN Proteinuria ACR eGFR (ml/min/1.73 m2)
Pre-HTN Stage 1 Stage 2 1+ 2+ 3+ 30–300 >300 30–59.9 15–29.9 <15
Prior CVD 20 7 (35) 7 (35) 5 (25) 7 (35) 4 (20) 2 (10) 0
– – – – – –
No prior CVD 1494 523 (35.4) 613 (41.5) 205 (13.9) 680 (45.5) 104 (7) 19 (1.3) 2 (0.1)
(33.0 to 37.9) (39.0 to 44.1) (12.2 to 15.7) (43.0 to 48.1) (5.7 to 8.4) (0.8 to 2.0) –
Georgia
All 1549 565 (36.5) 369 (23.8) 385 (24.9) 121 (7.9) 53 (3.4) 42 (2.7) 95 (56.5) 28 (16.7) 47 (3) 22 (1.4) 8 (0.5)
(34.1 to 39.0) (21.7 to 26.0) (22.7 to 27.1) (6.6 to 9.3) (2.6 to 4.5) (2.0 to 3.7) (48.7 to 64.2) (11.4 to 23.2) (2.2 to 4.0) (0.9 to 2.1) –
Gender
Women 1156 433 (37.5) 267 (23.1) 276 (23.9) 82 (7.2) 33 (2.9) 17 (1.5) 65 (56) 21 (18.1) 31 (2.7) 15 (1.3) 7 (0.6)
(34.7 to 40.4) (20.7 to 25.7) (21.5 to 26.5) (5.7 to 8.8) (2.0 to 4.0) (0.9 to 2.4) (46.5 to 65.2) (11.6 to 26.3) (1.8 to 3.8) (0.7 to 2.1) –
Men 393 132 (33.6) 102 (25.9) 109 (27.7) 39 (10) 20 (5.1) 25 (6.4) 30 (57.7) 7 (13.5) 16 (4.1) 7 (1.8) 1 (0.2)
(28.9 to 38.5) (21.7 to 30.6) (23.4 to 32.4) (7.2 to 13.4) (3.2 to 7.8) (4.2 to 9.3) (43.2 to 71.3) – (2.3 to 6.5) – –
Age (years)
18–40 405 180 (44.4) 62 (15.3) 38 (9.4) 20 (5) 6 (1.5) 7 (1.7) 10 (50) 1 (5) 4 (1) 2 (0.5) 0
(39.5 to 49.4) (11.9 to 19.2) (6.7 to 12.7) (3.1 to 7.6) – – (27.2 to 72.8) – – – –
41–60 731 279 (38.2) 192 (26.3) 179 (24.5) 54 (7.4) 20 (2.8) 22 (3) 45 (58.4) 13 (16.9) 11 (1.5) 10 (1.4) 4 (0.5)
(34.6 to 41.8) (23.1 to 29.6) (21.4 to 27.8) (5.6 to 9.6) (1.7 to 4.2) (1.9 to 4.6) (46.6 to 69.6) (9.3 to 27.1) (0.8 to 2.7) – –
>60 413 106 (25.7) 115 (27.8) 168 (40.7) 47 (11.5) 27 (6.6) 13 (3.2) 40 (56.3) 14 (19.7) 32 (7.7) 10 (2.4) 4 (1)
(21.5 to 30.2) (23.6 to 32.4) (35.9 to 45.6) (8.5 to 15.0) (4.4 to 9.4) (1.7 to 5.4) (44.0 to 68.1) (11.2 to 30.9) (5.4 to 10.8) – –
Prior DM 322 99 (30.7) 68 (21.1) 103 (31.9) 33 (10.4) 17 (5.3) 15 (4.7) 37 (66.1) 11 (19.6) 14 (4.3) 9 (2.8) 3 (0.9)
(25.7 to 36.1) (16.8 to 26.0) (26.9 to 37.4) (7.3 to 14.3) (3.1 to 8.4) (2.7 to 7.7) (52.2 to 78.2) (10.2 to 32.4) (2.4 to 7.2) – –
No prior DM 1095 407 (37.2) 272 (24.8) 247 (22.6) 83 (7.6) 30 (2.7) 25 (2.3) 53 (53.5) 15 (15.1) 27 (2.5) 12 (1.1) 5 (0.4)
(34.3 to 40.1) (22.3 to 27.5) (20.1 to 25.2) (6.1 to 9.4) (1.9 to 3.9) (1.5 to 3.4) (43.2 to 63.6) (8.7 to 23.8) (1.6 to 3.6) (0.6 to 1.9)
Prior CVD 196 64 (32.6) 41 (20.9) 75 (38.3) 23 (11.8) 10 (5.1) 11 (5.6) 16 (55.2) 7 (24.1) 10 (5.1) 6 (3.1) 2 (1)
(26.1 to 39.7) (15.4 to 27.3) (31.4 to 45.5) (7.6 to 17.2) – (2.8 to 9.9) (35.7 to 73.6) – – – –
No prior CVD 1170 417 (35.6) 286 (24.4) 272 (23.2) 91 (7.8) 35 (3) 28 (2.4) 70 (60.3) 17 (14.7) 30 (2.6) 14 (1.2) 6 (0.5)
(32.9 to 38.5) (22.0 to 27.0) (20.9 to 25.8) (6.4 to 9.5) (2.1 to 4.2) (1.6 to 3.5) (50.8 to 69.3) (8.8 to 22.4) (1.7 to 3.6) (0.7 to 2.0) –
Data are expressed as number (percentage) (CI).
CIs are not presented when relative SE>30%, because of unreliable estimates.
*Results for aged 20+ adults only.
†Measured by Albustick.
ACR, albumin creatinine ratio; CVD, cardiovascular disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HTN, hypertension.
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Bolivia, similar to that found in the US population by
NHANES. Hypertension, DM and obesity were relatively
common among these populations and clustered in sub-
jects with renal dysfunction. As expected, prevention
programmes in Bangladesh and Georgia focusing on
subjects with already known CVD risk factors such as
DM, hypertension or previous CV events found higher
prevalence of microalbuminuria. In accordance with
previously published studies, male gender was associated
with an increased prevalence of hypertension, reduced
renal function and proteinuria.10–12
The prevalence of renal dysfunction and microalbumi-
nuria found in Nepal and Bolivia is in line with those
reported by other ISN-sponsored screening programmes
in indigent residents of Guadalajara, Mexico13 or of
Kinshasa, in the Democratic Republic of Congo,14 high-
lighting the generalisability of this approach for case
detection in diverse settings around the world. Notably,
the availability of the NHANES dataset allowed us to
infer that the burden of CKD is similar across different
populations worldwide, including both high-income and
low-income countries. Importantly, data on the preva-
lence of albuminuria retrieved from the NHANES
cohort are similar to those reported by the Prevention
of Renal and Vascular ENd-stage Disease study, a large
European screening programme.15 This is consistent
with other evidence that chronic non-communicable dis-
eases are now the major cause of morbidity and mortal-
ity in the entire world.16–19 Intriguingly, prevalence of
CKD and of subjects with high CV risk was consistent
across different countries, independent of per capita
incomes (available at http://www.heritage.org/index/
default). Of note, prevalence of CKD in low-income
countries and in the USA was conﬁrmed when data were
corrected for different age distributions across nations.
In low-income countries, levels of physical activity were
higher than in the US population, whereas smoking
habit and alcohol consumption tended to be lower.
However, in light of progressive spread of Western life-
styles,20 incidence of DM and hypertension has been
forecast to increase in these nations during the next few
years, which is also expected to translate into increased
CKD and CVD. This clearly highlights the importance of
prevention programmes especially in low-income coun-
tries, where renal replacement therapies and coronary
revascularisation procedures are available only for a
minority of people.
About 15% of subjects had an estimated 10% or higher
risk of developing a CV risk in the following 10 years. In
consideration of the high prevalence of renal dysfunction
and microalbuminuria, this risk was probably underesti-
mated, although the net additional contribution of eGFR
and albuminuria on CVD risk is still unclear. Long term
outcome analysis of the present screened cohorts will
allow assessing whether inclusion of albuminuria and/or
reduced GFR among the variables considered in algo-
rithms for prediction of individual CVD risk will improve
the performance of current WHO prediction algorithms.
Evidence is emerging that CKD and CVD have a
major impact on macroeconomic development due to
diminished labour supply related to premature death
and disability in people of working age. According to
WHO, these conditions decrease the potential annual
growth rate in gross domestic product by 1–5% in devel-
oping countries experiencing rapid economic growth.21
Importantly, data from large trials have consistently
shown that off-patent drugs such as ACE inhibitors can
reduce albuminuria and prevent GFR decline and CV
events.5 Thus, prevention programmes should identify
and treat renal abnormalities early, with the primary
goal to reduce CV mortality and morbidity, which, on its
turn, may translate into an economical beneﬁt.
Table 4 Age-adjusted prevalence of eGFR<60 ml/min/1.73 m2 and ACR>30
n
eGFR<60 ml/min/1.73 m2 ACR>30
Unadjusted % % 95% CI Unadjusted % % 95% CI
Nepal
All 20811 19 22.1 21.5 to 22.7 7 7.8 7.2 to 8.4
Gender
Women 12792 21.3 26 25.2 to 26.8 6.4 7.1 6.3 to 7.9
Men 8019 15.3 16.8 16.0 to 17.6 8.1 8.8 7.8 to 9.8
Bolivia
All 3436 3.2 4 3.0 to 5.0 –
Gender
Women 2192 2.6 3.4 2.2 to 4.7 –
Men 1244 4.4 4.6 3.0 to 6.3 –
USA
All 4299 7.0 6.6 5.8 to 7.6 10.4 10.2 9.1 to 11.3
Gender
Women 2091 8.6 8.1 6.8 to 9.6 11.5 11.3 9.7 to 13.2
Men 2208 5.3 5.1 4.2 to 6.1 9.2 9.0 8.0 to 10.2
GFR<60 ml/min/1.73 m2 and A/C>30 estimates were age adjusted to the 2000 US standard population.
ACR, albumin creatinine ratio; eGFR, estimated glomerular filtration rate.
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Table 5 Prevalence of obesity/underweight and DM in participants by country
Participants (n)
BMI (kg/m2)
FPG>126 mg/dl<18.5 25–29.9 ≥30
Nepal
All 20811 2175 (10.5) 5478 (26.3) 1395 (6.7) 1227 (5.9)
(10.0 to 10.9) (25.7 to 26.9) (6.4 to 7.1) (5.6 to 6.3)
Gender
Women 12792 1291 (10.1) 3464 (27.1) 1073 (8.4) 650 (5.1)
(9.6 to 10.6) (26.3 to 27.9) (7.9 to 8.9) (4.7 to 5.5)
Men 8019 884 (11) 2014 (25.1) 322 (4) 577 (7.2)*
(10.4 to 11.7) (24.2 to 26.1) (3.6 to 4.5) (6.7 to 7.8)
Age (years)
18–40 11283 1323 (11.7) 2390 (21.2) 494 (4.4) 305 (2.7)
(11.1 to 12.3) (20.4 to 22.0) (4.0 to 4.8) (2.4 to 3.0)
41–60 6973 485 (7) 2430 (34.9) 718 (10.3) 648 (9.3)
(6.4 to 7.6) (33.7 to 36.0) (9.6 to 11.0) (8.7 to 10.0)
>60 2555 367 (14.4) 658 (25.8) 183 (7.2) 274 (10.7)
(13.0 to 15.8) (24.1 to 27.5) (6.2 to 8.2) (9.6 to 12.0)
Prior DM 1330 46 (3.5) 508 (38.2) 150 (11.3) 606 (45.7)
(2.5 to 4.6) (35.6 to 40.9) (9.6 to 13.1) (43.0 to 48.4)
No Prior DM 16623 1887 (11.4) 4160 (25) 988 (5.9) 573 (3.5)
(10.9 to 11.8) (24.4 to 25.7) (5.6 to 6.3) (3.2 to 3.8)
Prior CVD 304 20 (6.6) 91 (29.9) 32 (10.5) 35 (11.5)
(4.1 to 10.0) (24.8 to 35.4) (7.3 to 14.5) (8.2 to 15.7)
No Prior CVD 17737 1923 (10.8) 4602 (26) 1093 (6.2) 1070 (6.1)
(10.4 to 11.3) (25.3 to 26.6) (5.8 to 6.5) (5.7 to 6.4)
Bolivia
All 3436 57 (1.7) 1253 (36.5) 721 (21) 88 (2.6)
(1.3 to 2.1) (34.9 to 38.1) (19.6 to 22.4) (2.1 to 3.1)
Gender
Women 2192 31 (1.4) 767 (35) 553 (25.2) 52 (2.4)
(1.0 to 2.0) (33.0 to 37.0) (23.4 to 27.1) (1.8 to 3.1)
Men 1244 26 (2.1) 486 (39.1) 168 (13.5) 36 (2.9)
(1.4 to 3.0) (36.3 to 41.8) (11.7 to 15.5) (2.0 to 4.0)
Age (years)
18–40 1732 39 (2.2) 541 (31.2) 198 (11.4) 5 (0.3)
(1.6 to 3.1) (29.1 to 33.5) (10.0 to 13.0) –
41–60 1386 11 (0.8) 570 (41.1) 439 (31.7) 55 (4)
– (38.5 to 43.8) (29.2 to 34.2) (3.0 to 5.1)
>60 318 7 (2.2) 142 (44.6) 84 (26.4) 28 (8.8)
– (39.1 to 50.3) (21.7 to 31.6) (5.9 to 12.5)
Prior DM 87 0 32 (36.8) 34 (39.1) 87 (100)
(26.7 to 47.8) (28.8 to 50.1) –
No Prior DM 2392 38 (1.6) 863 (36.1) 506 (21.1) 0
(1.1 to 2.2) (34.1 to 38.0) (19.5 to 22.8)
Prior CVD 71 0 30 (42.2) 21 (29.6) 6 (8.4)
(30.6 to 54.6) (19.3 to 41.6) –
No Prior CVD 2718 44 (1.6) 984 (36.2) 571 (21) 76 (2.8)
(1.2 to 2.2) (34.4 to 38.0) (19.5 to 22.6) (2.2 to 3.5)
US
All 4299 77 (1.9) 1426 (33.2) 1489 (33.0) 478 (7.9)
(1.3 to 2.6) (31.4 to 35.0) (30.9 to 35.3) (7.0 to 8.9)
Gender
Women 2091 51 (2.5) 582 (27.3) 821 (35.4) 226 (7.5)
(1.9 to 3.4) (24.9 to 29.8) (32.9 to 38.0) (6.2 to 9.1)
Men 2208 26 (–) 844 (39.2) 668 (30.6) 252 (8.3)
(36.7 to 41.7) (27.7 to 33.7) (6.9 to 9.9)
Continued
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Table 5 Continued
Participants (n)
BMI (kg/m2)
FPG>126 mg/dl<18.5 25–29.9 ≥30
Age (years)
18–40 1652 40 (2.6) 484 (29.4) 497 (28.2) 48 (2.7)
(1.8 to 3.9) (26.5 to 32.5) (24.8 to 31.9) (1.9 to 3.8)
41–60 1337 19 (–) 477 (35.4) 522 (37.2) 152 (7.6)
(33.0 to 37.8) (34.0 to 40.5) (6.3 to 9.1)
>60 1310 18 (1.4) 465 (36.5) 470 (35.0) 278 (18.6)
(0.9 to 2.1) (33.0 to 40.2) (32.3 to 37.7) (16.5 to 20.9)
Prior DM 516 2 (–) 140 (24.4) 299 (61.3) 329 (62.4)
(19.7 to 29.9) (55.4 to 66.9) (57.2 to 67.3)
No prior DM 3779 75 (2.0) 1284 (34.0) 1189 (30.5) 148 (2.9)
(1.4 to 2.8) (31.9 to 36.1) (28.4 to 32.7) (2.3 to 3.7)
Prior CVD 467 6 (–) 146 (31.6) 212 (45.2) 115 (21.2)
(27.2 to 36.4) (38.8 to 51.8) (17.3 to 25.7)
No prior CVD 3493 56 (1.7) 1199 (33.6) 1207 (32.5) 355 (6.8)
(1.2 to 2.5) (31.8 to 35.6) (30.3 to 34.7) (6.0 to 7.6)
Bangladesh
All 1518 307 (20.2) 215 (14.1) 22 (1.4) 132 (9.6)
(18.2 to 22.3) (12.4 to 16.0) (0.9 to 2.2) (8.1 to 11.2)
Gender
Women 859 155 (18) 128 (14.9) 15 (1.7) 78 (9.9)
(15.5 to 20.8) (12.6 to 17.5) (1.0 to 2.9) 7.9 to 12.2)
Men 659 152 (23.1) 87 (13.2) 7 (1.1) 54 (9.1)
(19.9 to 26.5) (10.7 to 16.0) – (6.9 to 11.6)
Age (years)
18–40 575 135 (23.5) 103 (17.9) 8 (1.4) 46 (9.1)
(20.1 to 27.2) (14.9 to 21.3) – (6.7 to 11.9)
41–60 690 97 (14.1) 86 (12.5) 13 (1.9) 65 (10)
(11.6 to 16.9) (10.1 to 15.2) (1.0 to 3.2) (7.8 to 12.6)
>60 253 75 (29.6) 26 (10.3) 1 (0.4) 21 (9.3)
(24.1 to 35.7) (6.8 to 14.7) – (5.8 to 13.9)
Prior DM 111 8 (7.2) 17 (15.3) 10 (9.1) 24 (23.5)
– (9.2 to 23.4) – (15.7 to 33.0)
No Prior DM 1404 297 (21.1) 198 (14.1) 12 (0.8) 108 (8.5)
(19.0 to 23.4) (12.3 to 16.0) (0.4 to 1.5) (7.0 to 10.1)
Prior CVD 20 4 (20) 4 (20) 3 (15) 3 (16.7)
– – – –
No Prior CVD 1494 301 (20.1) 211 (14.1) 19 (1.2) 129 (9.5)
(18.1 to 22.3) (12.4 to 16.0) (0.8 to 2.0) (8.0 to 11.2)
Georgia
All 1549 41 (2.6) 498 (32.1) 580 (37.4) 232 (15.2)
(1.9 to 3.6) (29.8 to 34.5) (35.0 to 39.9) (13.4 to 17.1)
Gender
Women 1156 33 (2.8) 370 (32) 450 (38.9) 170 (14.9)
(2.0 to 4.0) (29.3 to 34.8) (36.1 to 41.8) (12.9 to 17.1)
Men 393 8 (2) 128 (32.6) 130 (33.1) 62 (16.1)
– (28.0 to 37.4) (28.4 to 38.0) (12.5 to 20.1)
Age (years)
18–40 405 28 (6.9) 105 (25.9) 74 (18.3) 38 (9.5)
(4.6 to 9.8) (21.7 to 30.5) (14.6 to 22.4) (6.8 to 12.8)
41–60 731 8 (1.1) 233 (31.9) 349 (47.7) 104 (14.4)
– (28.5 to 35.4) (44.1 to 51.4) (12.0 to 17.2)
>60 413 5 (1.2) 160 (38.7) 157 (38) 90 (22.1)
– (34.0 to 43.6) (33.3 to 42.9) (18.1 to 26.4)
Prior DM 322 7 (2.2) 95 (29.5) 142 (44.1) 166 (52.2)
– (24.6 to 34.8) (38.6 to 49.7) (46.6 to 57.8)
Continued
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There is little debate that screening for albuminuria
should be performed in patients with DM and/or hyper-
tension, where early intervention can slow down deteri-
oration of renal function. However, due to the difﬁculty
of identifying subjects at risk in low-income countries, a
prescreening phase including clinical history, BP and
anthropometric values might be instrumental in identify-
ing patients in whom screening with serum and urine
testing could be most cost-effective. On the contrary,
data from Nepal and Bolivia showed that more than 5%
of people younger than 60 years without previous history
of diabetes and hypertension had microalbuminuria/
proteinuria. Consistently, screening also low-risk groups,
or even the general population, has been advocated to
identify and treat those at risk for progressive renal
disease, arguing that most persons with albuminuria
and/or reduced eGFR (<60 ml/min/1.73 m2) are
asymptomatic. However, concerns towards general popu-
lation screenings regard not only the cost of screening
itself, but, more importantly, the risk and the cost of
treating false-positive subjects with no other modiﬁable
risk factors. Thus, patients with a ﬁrst positive test should
be always asked to repeat the analyses and only those
with conﬁrmed positivity should be treated.22 However,
when debating how to address the issue of screening for
non-communicable diseases and, more in general, of
health in developing nations, we should look at the
problem from the perspective of the low-income and
middle-income countries, not from that of industrialised
nations. Indeed, there is not a unique blueprint of
screening strategy even among developing countries, so
that the approaches should be adapted on single-nation
conditions and socioeconomic status.23
Strengths and limitations of the study
Our study has several limitations. At variance with
NHANES data, showing characteristics of a cohort repre-
sentative of US population, results from Bolivia cannot
be taken to infer the absolute or relative prevalence of
renal abnormalities in this country, since all subjects
were referred to a single centre. However, in consider-
ation of the limited availability of local resources,
current data seem reasonably reliable and representative
of a large fraction of people, at least those living at the
altitude regions of this country. Reliability of data is sup-
ported by the fact that, in line with available evidence,
prevalence of microalbuminuria was higher in older sub-
jects and in those with hypertension or diabetes. Also
data from Nepal cannot be formally considered repre-
sentative of the whole Nepalese population. However,
the multiple sites used for the screening, along with the
large sample size and consistency with data retrieved
from a previous smaller cohort of Nepalese subjects24
make the present dataset insightful of the prevalence of
CKD and CVD in this nation. Importantly, data from
Bolivia were similar to those found in Nepal and this
Table 6 Cardiovascular risk distribution in participants by country
Country Participants
10-year cardiovascular risk
<10 10.1–20 20.1–30 30.1–40 >40
Nepal 5187 4309 (83.1) 829 (16.0) 33 (0.6) 9 (0.2) 7 (0.1)
(82.0 to 84.1) (15.0 to 17.0) (0.4 to 0.9) – –
Bolivia 601 545 (90.7) 43 (7.2) 9 (1.5) 3 (0.5) 1 (0.2)
(88.1 to 92.9) (5.2 to 9.5) – – –
USA 1093 794 (81.8) 193 (12.3) 56 (3.0) 31 (1.7) 19 (–)
(79.3 to 84.1) (10.3 to 14.6) (2.3 to 4.0) (1.0 to 2.7) –
Bangladesh 758 566 (74.7) 143 (18.9) 33 (4.4) 9 (1.2) 7 (0.9)
(71.4 to 77.7) (16.1 to 21.8) (3.0 to 6.1) – –
Georgia 927 695 (75.0) 106 (11.4) 78 (8.4) 28 (3.0) 20 (2.2)
(72.1 to 77.7) (9.5 to 13.7) (6.7 to 10.4) (2.0 to 4.3) (1.3 to 3.3)
Data are expressed as number (percentage) (CI). CIs are not presented when relative SE>30% because of unreliable estimates.
Table 5 Continued
Participants (n)
BMI (kg/m2)
FPG>126 mg/dl<18.5 25–29.9 ≥30
No Prior DM 1095 31 (2.8) 367 (33.5) 382 (34.9) 48 (4.4)
(1.9 to 4.0) (30.7 to 36.4) (32.1 to 37.8) (3.3 to 5.8)
Prior CVD 196 1 (0.5) 60 (30.6) 96 (49) 36 (18.6)
– (24.2 to 37.6) (41.8 to 56.2) (13.4 to 24.9)
No Prior CVD 1170 35 (3) 388 (33.2) 402 (34.4) 162 (14)
(2.1 to 4.1) (30.5 to 35.9) (31.6 to 37.2) (12.1 to 16.2)
Data are expressed as number (percentage) (CI). CIs are not presented when relative SE>30%, because of unreliable estimates.
*p<0.05 versus women.
BMI, body mass index; CVD, cardiovascular disease; DM, diabetes mellitus; FPG, fasting plasma glucose.
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suggests that these data may reﬂect patterns throughout
the developing world. Of note, although formal com-
parison across different populations is prevented by dif-
ferent inclusion criteria and sampling strategies, use of
the same cut-off points for clinical and laboratory para-
meters and the same web-based database for data entry
and centralised data monitoring make the present ana-
lysis a unique opportunity to study prevalence of CKD
and CVD in countries with different incomes.
Owing to limited resources, laboratories in developing
countries were not calibrated according to the National
Kidney Disease Education Program. However, each site
made calibrations for creatinine measurement according
to guidelines suggested by the manufacture, which
should have prevented major bias in our ﬁndings. Some
authors have advocated to repeat renal function mea-
surements in screening programmes to prevent overesti-
mation of disease prevalence.22 However, in low-income
countries, repeated measurements on a standard basis
would unnecessarily increase costs and could be bur-
dened by high rate of non-compliance, which, on its
turn, could reduce the number of subjects identiﬁed
with renal abnormalities. In addition, the primary goal
of any screening programme is to avoid false negative
results that might affect the identiﬁcation of subjects at
risk, whereas the risk of false-positive results is of rela-
tively limited importance since subjects erroneously
identiﬁed with albuminuria can be correctly charac-
terised at follow-up evaluation. Therefore, different
assays to measure albuminuria should be titrated to
single resources. Consistently, a pilot phase of National
Kidney Foundation Kidney Early Evaluation Program in
México City and Jalisco State25 reporting prevalence of
eGFR<60 ml/min/1.73 m2 and albuminuria close to the
ones we found in high-risk subjects from Georgia and
Bangladesh, evaluated albuminuria levels once and used
the same cut-off points considered in our analyses.
Finally, an issue of the present study was the use of
GFR-predicting equations that may not fully ﬁt to differ-
ent ethnicities, thus some participants from these coun-
tries might have been misclassiﬁed with respect to the
presence of eGFR<60 ml/min/1.73 m2. This could
account for the variability across different countries. On
the contrary, performance of formulas is poor for high
levels of GFR, whereas they tend to improve for lower
values. Thus, risk of misclassiﬁcation of subjects below
the threshold of 60 ml/min/1.73 m2 is reasonably low.
Notably, since no ad hoc formulas are available to esti-
mate GFR more precisely in considered populations,
such ISN screening programmes might offer the unique
opportunity to implement formulas to ﬁt best different
ethnicities.
CONCLUSIONS
We found that impaired kidney function and microalbu-
minuria/proteinuria are common within the general
population, both in low-income countries and in the
USA. Although screening programmes focusing on high-
risk subjects seem to be more cost-effective than general
population screenings, overall these data demonstrate
the feasibility of projects for early detection of CKD in
low-income nations. In the light of major impact of
renal abnormalities on CVD, these programmes are
urgently warranted and should be implemented accord-
ing to single-nation characteristics. Prospective studies
are ongoing26 and will allow quantifying the beneﬁts of
such prevention strategies.
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APPENDIX
Screening programme in emerging countries—study
organisation
Nepal
Principal investigator: Sanjib Kumar Sharma
Study group: Sanjeev Thapa, Anil Basnet, Madhav Ghimire, Bishnu
Pahari, Hemanta Shrestha, Murari Barakoti, Mahesh Bhattarai M,
Suchaya Parikh, Santosh Raout, Ram Chandra Kafle, Krishna Kumar
Agrawal, Denish Peeyush, Khechar Paudel, Nabin Pandey, Sarita
Kumari, Puru Koirala, Navaraj Paudel, Niraj Kumar Jaiswal, Vivek
Kattel, Philip Urban, Sujata Rai, Sunira Karki, Mamta Dev, Bangbu
Tamang, Mamit Rai, Kajiman Giri, Tofa Limbu. In addition the
medical students, the nursing students and staff, the administrators of
BPKIHS, various local organisations and leaders, The Redcross of
Damak, Sahara Nepal of Biratamod, the media house and reporters
form Dharan and Civil Society of Dharan.
Bolivia
Principal investigator: Rodolfo Flores Bravo
Study group: Andrea Alejandra Panozo Rivero, Rocio Adrina Alarcon
Terrazas, Elizabeth Joyce Mealla Black, Rocio Miranda Choque,
Agustina Anabaya, Ayde Agudo.
Bangladesh
Principal investigator: Nazmul Islam
Study group: Mohammad Kamruzzaman, Mokbul Hussain, Tofazzal
Hussain, Sujan Miah, Al-Mamun Khan, Anjan Kumar Das,Atiqul Islam,
Rezwan Ahmed, Shafiqul Islam. In addition, the Patron of Abdul
Khalique Borbhuiya, Shahriah Hossain Chowdhury, Mohammad Afzal
Miah.
Georgia
Principal investigator: Irma Tchokhonelidze
Study group: Avtandil Tataradze, Tinatin Davitaia, Lela Beglarashvili,
Nino Khizanishvili, Natia Dvaladze, Lali Bibileishvili
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